Thus, compounds that prevent the participation of GAPDH in aggregation processes in Huntington’s disease, such as deprenyl [20], and in oxidative stress accompanying Alzheimer’s disease, such as GAI [40], have been proposed as neuroprotective agents. Here, GAPDH is linked to Huntington disease.